Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

BioVex Inc.

Division of Amgen Inc.
www.biovex.com

Latest From BioVex Inc.

R&D Head Sean Harper On Amgen's Long-Term Investment View

Amgen is validating targets through the deCODE Genetics investment it made five years and moving drugs into the clinic. It's one of multiple technologies – along with its BiTE and oncolytic virus platforms – that R&D head Sean Harper said is starting to bear fruit for the company.

Business Strategies Research and Development Strategies

Profile: VC Forbion's Slootweg Sees Bigger And Better European Funds

Sander Slootweg, managing partner and co-founder of Forbion Capital Partners, talks venture capital trends, industrial changes to watch, deal making and challenges faced during his years investing in the life science industry in the latest instalment of Scrip's executive profile series.

Leadership Financing

How To Get Ahead In The Trendy World Of Immuno-Oncology

With basic research in immuno-oncology still very limited, there are still a lot of opportunities to develop new breakthrough therapies beyond checkpoint inhibitors, companies active in the space said during a panel at the recent Biotech Showcase.

Clinical Trials Research and Development Strategies

Melanoma Approvals Break New Ground In Immunotherapy

First adjuvant and combination approvals for immuno-oncology could help revive Yervoy in melanoma; Amgen’s oncolytic cancer vaccine emerges as new mechanism for select patients, with room to grow.

Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
    • Vaccines
  • Therapeutic Areas
  • Cancer
  • Immune Disorders
  • Infectious & Viral Diseases
  • Alias(es)
  • BioVex Group Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amgen Inc.
  • Senior Management
  • Stephen Gorgol, CFO
    Colin Love, PhD, SVP, Prod. Dev.
    Pamela Esposito, VP, Bus. Dev.
  • Contact Info
  • BioVex Inc.
    Phone: (781) 376-4900
    34 Commerce Way
    Woburn, MA 01801
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register